These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 16061457)

  • 1. Non-medical use of OxyContin Tablets in the United States.
    Sees KL; Di Marino ME; Ruediger NK; Sweeney CT; Shiffman S
    J Pain Palliat Care Pharmacother; 2005; 19(2):13-23. PubMed ID: 16061457
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Internet-based survey of nonmedical prescription opioid use in the United States.
    Katz N; Fernandez K; Chang A; Benoit C; Butler SF
    Clin J Pain; 2008; 24(6):528-35. PubMed ID: 18574362
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trends in abuse of Oxycontin and other opioid analgesics in the United States: 2002-2004.
    Cicero TJ; Inciardi JA; Muñoz A
    J Pain; 2005 Oct; 6(10):662-72. PubMed ID: 16202959
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gender and non-medical use of prescription opioids: results from a national US survey.
    Tetrault JM; Desai RA; Becker WC; Fiellin DA; Concato J; Sullivan LE
    Addiction; 2008 Feb; 103(2):258-68. PubMed ID: 18042194
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incidence of nonmedical use of OxyContin and other prescription opioid pain relievers before and after the introduction of OxyContin with abuse deterrent properties.
    Cheng HG; Coplan PM
    Postgrad Med; 2018 Aug; 130(6):568-574. PubMed ID: 29978755
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The development of a comprehensive risk-management program for prescription opioid analgesics: researched abuse, diversion and addiction-related surveillance (RADARS).
    Cicero TJ; Dart RC; Inciardi JA; Woody GE; Schnoll S; Muñoz A
    Pain Med; 2007 Mar; 8(2):157-70. PubMed ID: 17305687
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prescription Opioid Misuse Index: a brief questionnaire to assess misuse.
    Knisely JS; Wunsch MJ; Cropsey KL; Campbell ED
    J Subst Abuse Treat; 2008 Dec; 35(4):380-6. PubMed ID: 18657935
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Abuse-Deterrent Formulations and the Prescription Opioid Abuse Epidemic in the United States: Lessons Learned From OxyContin.
    Cicero TJ; Ellis MS
    JAMA Psychiatry; 2015 May; 72(5):424-30. PubMed ID: 25760692
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of FDA approval of a generic competitor to OxyContin (oxycodone HCl controlled-release) tablets on the abuse of oxycodone.
    Bailey JE; Barton PL; Lezotte D; Lowenstein SR; Dart RC
    Drug Alcohol Depend; 2006 Sep; 84(2):182-7. PubMed ID: 16510252
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Non-medical use, abuse and dependence on prescription opioids among U.S. adults: psychiatric, medical and substance use correlates.
    Becker WC; Sullivan LE; Tetrault JM; Desai RA; Fiellin DA
    Drug Alcohol Depend; 2008 Apr; 94(1-3):38-47. PubMed ID: 18063321
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Estimating attractiveness for abuse of a not-yet-marketed "abuse-deterrent" prescription opioid formulation.
    Butler SF; Black R; Grimes Serrano JM; Folensbee L; Chang A; Katz N
    Pain Med; 2010 Jan; 11(1):81-91. PubMed ID: 20002324
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A profile of OxyContin addiction.
    Hays LR
    J Addict Dis; 2004; 23(4):1-9. PubMed ID: 15339710
    [TBL] [Abstract][Full Text] [Related]  

  • 13. OxyContin abuse and overdose.
    Aquina CT; Marques-Baptista A; Bridgeman P; Merlin MA
    Postgrad Med; 2009 Mar; 121(2):163-7. PubMed ID: 19332974
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Trends in the Nonmedical Use of OxyContin, United States, 2006 to 2013.
    Jones CM; Muhuri PK; Lurie PG
    Clin J Pain; 2017 May; 33(5):452-461. PubMed ID: 27513641
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Attractiveness of reformulated OxyContin(R) tablets: assessing comparative preferences and tampering potential.
    Sellers EM; Perrino PJ; Colucci SV; Harris SC
    J Psychopharmacol; 2013 Sep; 27(9):808-16. PubMed ID: 23784739
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Non-medical use and abuse of commonly prescribed medications.
    Riggs P
    Curr Med Res Opin; 2008 Mar; 24(3):869-77. PubMed ID: 18267053
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of abuse-deterrent OxyContin on prescription opioid utilization.
    Hwang CS; Chang HY; Alexander GC
    Pharmacoepidemiol Drug Saf; 2015 Feb; 24(2):197-204. PubMed ID: 25393216
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluating the potential impact of a reformulated version of oxycodone upon tampering, non-adherence and diversion of opioids: the National Opioid Medications Abuse Deterrence (NOMAD) study protocol.
    Degenhardt L; Larance B; Bruno R; Lintzeris N; Ali R; Farrell M
    Addiction; 2015 Feb; 110(2):226-37. PubMed ID: 25358480
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Substance use histories in patients seeking treatment for controlled-release oxycodone dependence.
    Potter JS; Hennessy G; Borrow JA; Greenfield SF; Weiss RD
    Drug Alcohol Depend; 2004 Nov; 76(2):213-5. PubMed ID: 15488345
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic opioids: a ten-year perspective on the complexities and complications of the escalating use, abuse, and nonmedical use of opioids.
    Manchikanti L; Singh A
    Pain Physician; 2008 Mar; 11(2 Suppl):S63-88. PubMed ID: 18443641
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.